IκB kinase-α regulates endothelial cell motility and tumor angiogenesis

Cancer Research

Volumn 68, Issue 24, 2008, Pages 10223-10228

  DeBusk, Laura M ^a   Massion, Pierre P ^a   Charles Lin, P ^a,b  

^a VANDERBILT INGRAM CANCER CENTER   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

I KAPPA B KINASE ALPHA; I KAPPA B KINASE BETA; I KAPPA B KINASE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER TRANSPLANTATION; CELL MOTILITY; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME INHIBITION; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; BIOSYNTHESIS; CELL CULTURE; CELL MOTION; ENZYMOLOGY; GENETICS; LEWIS CARCINOMA; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; PHYSIOLOGY; UPREGULATION; VASCULARIZATION;

ANIMALS; CARCINOMA, LEWIS LUNG; CELL MOVEMENT; CELLS, CULTURED; ENDOTHELIAL CELLS; FEMALE; HUMANS; I-KAPPA B KINASE; MICE; NEOVASCULARIZATION, PATHOLOGIC; UP-REGULATION;

EID: 57749121470     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-1833     Document Type: Article

References (24)

1. Karin M. Nuclear factor-κB in cancer development and progression. Nature 2006;441:431-6.
2. Kim HJ, Hawke N, Baldwin AS. NF-κB and IKK as therapeutic targets in cancer. Cell Death Differ 2006;13:738-47.
3. Basseres DS, Baldwin AS. Nuclear factor-κB and inhibitor of κB kinase pathways in oncogenic initiation and progression. Oncogene 2006;25:6817-30.
4. Ghosh S, Karin M. Missing pieces in the NF-κB puzzle. Cell 2002;109 Suppl:S81-96.
5. Baldwin AS, Jr. The NF-κB and IκB proteins: new discoveries and insights. Annu Rev Immunol 1996;14:649-83.
6. Takaesu G, Surabhi RM, Park KJ, et al. TAK1 is critical for IκB kinase-mediated activation of the NF-κB pathway. J Mol Biol 2003;326:105-15.
7. Solt LA, Madge LA, Orange JS, et al. Interleukin-1-induced NF-κB activation is NEMO-dependent but does not require IKKβ. J Biol Chem 2007;282:8724-33.
8. Senftleben U, Cao Y, Xiao G, et al. Activation by IKKα of a second, evolutionary conserved, NF-κB signaling pathway. Science 2001;293:1495-9.
9. Anest V, Hanson JL, Cogswell PC, et al. A nucleosomal function for IκB kinase-α in NF-κB-dependent gene expression. Nature 2003;423:659-63.
10. Yamamoto Y, Verma UN, Prajapati S, et al. Histone H3 phosphorylation by IKK-α is critical for cytokine-induced gene expression. Nature 2003;423:655-9.
11. Jobin C, Panja A, Hellerbrand C, et al. Inhibition of proinflammatory molecule production by adenovirus-mediated expression of a nuclear factor κB super-repressor in human intestinal epithelial cells. J Immunol 1998;160:410-8.
12. Lin P, Buxton JA, Acheson A, et al. Antiangiogenic gene therapy targeting the endothelium-specific receptor tyrosine kinase Tie2. Proc Natl Acad Sci U S A 1998;95:8829-34.
13. Kamiyama M, Pozzi A, Yang L, et al. EP2, a receptor for PGE2, regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 2006;25:7019-28.
14. Brantley-Sieders DM, Fang WB, Hicks DJ, et al. Impaired tumor microenvironment in EphA2-deficient mice inhibits tumor angiogenesis and metastatic progression. FASEB J 2005;19:1884-6.
15. Yang L, Debusk LM, Fukuda K, et al. Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004;6:409-21.
16. Kobayashi H, DeBusk LM, Babichev YO, et al. Hepatocyte growth factor mediates angiopoietin-induced smooth muscle cell recruitment. Blood 2006;108:1260-6.
17. Hu Y, Baud V, Delhase M, et al. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science 1999;284:316-20.
18. Hu Y, Baud V, Oga T, et al. IKKα controls formation of the epidermis independently of NF-κB. Nature 2001;410:710-4.
19. Ohazama A, Hu Y, Schmidt-Ullrich R, et al. A dual role for Ikk α in tooth development. Dev Cell 2004;6:219-27.
20. Agarwal A, Das K, Lerner N, et al. The AKT/I κ B kinase pathway promotes angiogenic/metastatic gene expression in colorectal cancer by activating nuclear factor-κ B and β-catenin. Oncogene 2005;24:1021-31.
21. Marumo T, Schini-Kerth VB, Busse R. Vascular endothelial growth factor activates nuclear factor-κB and induces monocyte chemoattractant protein-1 in bovine retinal endothelial cells. Diabetes 1999;48:1131-7.
22. Kim I, Moon SO, Kim SH, et al. Vascular endothelial growth factor expression of intercellular adhesion molecule 1 (ICAM-1), vascular cell adhesion molecule 1 (VCAM-1), and E-selectin through nuclear factor-κ B activation in endothelial cells. J Biol Chem 2001;276:7614-20.
23. DeBusk LM, Hallahan DE, Lin PC. Akt is a major angiogenic mediator downstream of the Ang1/Tie2 signaling pathway. Exp Cell Res 2004;298:167-77.
24. Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 2006;25:6887-99.